Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000728095 | SCV000855628 | uncertain significance | not provided | 2017-07-07 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001407781 | SCV001609763 | likely benign | Cystic fibrosis | 2022-03-29 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001407781 | SCV002612952 | uncertain significance | Cystic fibrosis | 2015-08-14 | criteria provided, single submitter | clinical testing | The c.3368-4A>G intronic variant results from an A to G substitution 4 nucleotides upstream from coding exon 21 in the CFTR gene. This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6503 samples (13006 alleles) with coverage at this position. This nucleotide position is not well conserved in available vertebrate species. Using two different splice site prediction tools, this alteration is predicted by BDGP to weaken the efficacy of the native acceptor splice site, but is not predicted to have a deleterious effect on this acceptor splice site by ESEfinder; however, direct evidence is unavailable. Since supporting evidence is limited at this time, the clinical significance of this variant remains unclear. |